Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Long term follow-up report of cardiac toxicity in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation
Authors:ID Koželj, Mirta (Author)
ID Zver, Samo (Author)
ID Zadnik, Vesna (Author)
Files:.pdf PDF - Presentation file, download (288,46 KB)
MD5: 3C04C2F325D7E64421E870B34F9C3DD4
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:Background. Tandem autologous hematopoietic stem cell transplantation (ta-HSCT) is a standard treatment for multiple myeloma (MM). Patients receive a high-dose cyclophosphamide (CY), followed by two myeloablative cycles of melphalan (MEL). There are scarce data about long term cardiotoxicity. Patients and methods. We studied 12 patients (62.25 8.55 years) six years after the completion of MM treatment with ta-HCST. Late cardiotoxic effects were evaluated clinically and echocardiographically. Results. None of the patients developed clinical signs of heart failure, all were in sinus rhythm and NT-pro BNP concentration was elevated (778 902.76 pg/mL). The left ventricular (LV) size remained normal. The LV ejection fraction did not decrease (73.75 5.67%, 69.27 6.13%, p = NS). The LV diastolic function parameters (E, A, ratio E/A and A/a) did not change significantly. In tissue Doppler parameters we observed a nonsignificant decrease in Em (10.26 2.63 cm/s, 7.57 1.43 cm/s) and Sm velocities (8.7 0.87 cm/s, 7.14 1.17 cm/s, p = NS). The E/Em values were in an abnormal range (8.66 1.05, 10.55 2.03). Conclusions. The treatment of MM with ta-HSCT, during which patients receive a high dose CY followed by two myeloablative cycles of MEL, causes mild, chronic, partially reversible and clinically silent cardiotoxic side-effects. However, ta-HSCT in patients with MM is a safe regarding cardiotoxic side effects, but, because of increasing life expectancy needs long term attention.
Keywords:cardiotoxicity, echocardiography, myeloma
Publication status:Published
Publication version:Version of Record
Publication date:01.06.2013
Publisher:Association of Radiology and Oncology
Year of publishing:2013
Number of pages:str. 161-165, V
Numbering:Vol. 47, no. 2
Source:Ljubljana
PID:20.500.12556/DiRROS-18541 New window
UDC:616-006
ISSN on article:1318-2099
DOI:10.2478/raon-2013-0019 New window
COBISS.SI-ID:1577595 New window
Copyright:by Authors
Publication date in DiRROS:22.03.2024
Views:495
Downloads:151
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Radiology and oncology
Shortened title:Radiol. oncol.
Publisher:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 New window

Secondary language

Language:Slovenian
Keywords:kardiotoksičnost, cyclophosphamide, melphalan, ultrazvočni zapis, mielomi


Back